Journal
ACS CHEMICAL BIOLOGY
Volume 8, Issue 8, Pages 1698-1703Publisher
AMER CHEMICAL SOC
DOI: 10.1021/cb4002014
Keywords
-
Categories
Funding
- Swedish Foundation for Strategic Research [RBc08-0014]
- Swiss National Foundation [310030B-138667]
- Swedish Research Council
- Umea University
- Swedish Foundation for Strategic Research (SSF) [RBc08-0014] Funding Source: Swedish Foundation for Strategic Research (SSF)
Ask authors/readers for more resources
Inhibiting ADP-ribosyl transferases with PARP-inhibitors is considered a promising strategy for the treatment of many cancers and ischemia, but most of the cellular targets are poorly characterized. Here, we describe an inhibitor of ADP-ribosyltransferase-3/poly(ADP-ribose) polymerase-3 (ARTD3), a regulator of DNA repair and mitotic progression. In vitro profiling against 12, members of the enzyme family suggests selectivity for ARTD3, and crystal structures illustrate the molecular basis for inhibitor selectivity. The compound is active in cells, where it elicits ARTD3-specific effects at submicromolar concentration. Our results show that by targeting the nicotinamide binding site, selective inhibition can be achieved among the closest relatives of the validated clinical target, ADP-ribosyltransferase-1/poly(ADP-ribose) polymerase-1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available